Direxion NASDAQ-100 Equal Weighted Index Shares
QQQE - ETF AI Analysis
Top Page
Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE)
QQQE’s rating suggests it is a solid, but not top-tier, ETF, helped by strong, diversified holdings in areas like healthcare and technology. Leaders such as Regeneron, Gilead Sciences, Texas Instruments, Analog Devices, and Intuitive Surgical support the fund with robust financial performance, innovation, and generally positive long-term outlooks. The main risk is that several of these key holdings trade at high valuations and show signs of being overbought, which could make the ETF more sensitive to market pullbacks.
QQQE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.41B
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 1.09
- Issuer
- Direxion
- Inception Date
- Mar 21, 2012
- Dividend Yield
- 0.60%
- Asset Class
- Equity
- Index Tracked
- NASDAQ-100 Equally Weighted Index
QQQE Summary
QQQE is an ETF that tracks the NASDAQ-100 Equally Weighted Index, meaning it invests in 100 of the largest companies on the NASDAQ but gives each one a similar size in the fund instead of letting the biggest dominate. It holds well-known names like Meta Platforms and Walmart, across sectors such as technology, consumer companies, and healthcare. Someone might invest in QQQE to get diversified exposure to many leading growth companies without being overly concentrated in a few tech giants. A key risk is that it can still rise and fall sharply with the overall stock market and the tech-heavy NASDAQ.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s a bit higher than the cheapest index ETFs because QQQE uses a more specialized equal-weight strategy rather than a plain, passively managed market-cap index.
What would affect this ETF?
Future performance of QQQE will be helped by strong growth in U.S. technology, consumer, and healthcare companies, especially if innovation, digital spending, and economic conditions stay healthy, allowing its equal-weight approach to benefit from a broad range of NASDAQ-100 stocks rather than just the biggest names. On the downside, rising interest rates, a slowdown in the U.S. economy, tighter tech regulation, or weak consumer spending could hurt many of its top holdings like chip makers, online platforms, and retailers at the same time, increasing volatility for the fund.
QQQE Top 10 Holdings
QQQE spreads its bets evenly, but the story still centers on tech. Chip names like AMD and Marvell have been key engines, with AMD rising over the year while Marvell’s more recent pullback has taken a bit of wind out of the sails. Software and cloud plays such as Datadog and CrowdStrike are steadily adding fuel, even if rich valuations keep them on a tighter leash. Outside tech, Moderna has been a surprising bright spot, while Intuitive Surgical’s mixed showing reminds investors this U.S.-heavy, NASDAQ-focused fund isn’t all smooth sailing.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MRNA | Moderna | 1.44% | $20.76M | $101.49B | 841.65% | 59Neutral |
 APP | AppLovin | 1.33% | $19.22M | $131.04B | -31.96% | 74Outperform |
 MAR | Marriott International | 1.29% | $18.61M | $110.28B | 47.03% | 62Neutral |
 IDXX | Idexx Laboratories | 1.30% | $18.70M | $54.89B | -1.39% | 78Outperform |
 ISRG | Intuitive Surgical | 1.23% | $17.67M | $156.00B | -21.43% | 78Outperform |
 WMT | Walmart | 1.23% | $17.75M | $996.08B | 21.49% | 78Outperform |
 GEHC | GE Healthcare Technologies Inc | 1.19% | $17.18M | $37.82B | 12.52% | 78Outperform |
 KDP | Keurig Dr Pepper | 1.23% | $17.79M | $51.16B | 43.10% | 71Outperform |
 GILD | Gilead Sciences | 1.19% | $17.18M | $211.94B | 38.49% | 78Outperform |
 REGN | Regeneron | 1.23% | $17.79M | $94.75B | 42.23% | 78Outperform |
QQQE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QQQE, the sentiment is Positive. The current price of 117.70 is above the 20-day moving average (MA) of 117.05, below the 50-day MA of 118.78, and above the 200-day MA of 113.28, indicating a neutral trend. The MACD of -1.20 indicates Positive momentum. The RSI at 50.78 is Neutral, neither overbought nor oversold. The STOCH value of 64.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QQQE.
QQQE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| QQQE | $117.70 | $128.00(8.75% Upside) | $1.41B | 0.35% | 70Outperform |
 PRF | $56.79 | $65.05(14.54% Upside) | $10.14B | 0.34% | 72Outperform |
 MGC | $278.10 | $347.76(25.05% Upside) | $10.01B | 0.05% | 75Outperform |
 JQUA | $76.21 | $89.02(16.80% Upside) | $9.86B | 0.12% | 73Outperform |
 VONE | $344.06 | $431.09(25.30% Upside) | $9.40B | 0.06% | 73Outperform |
 QEW | $29.16 | $36.43(24.94% Upside) | $31.38M | 0.25% | 70Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QQQE | Direxion NASDAQ-100 Equal Weighted Index Shares | 117.70 | 17.71 | 17.71% | |
| PRF | Invesco FTSE RAFI US 1000 ETF | 56.79 | 11.78 | 26.16% | |
| MGC | Vanguard Mega Cap ETF | 278.10 | 33.14 | 13.53% | |
| JQUA | JPMorgan U.S. Quality Factor ETF | 76.21 | 14.93 | 24.36% | |
| VONE | Vanguard Russell 1000 ETF | 344.06 | 43.15 | 14.34% | |
| QEW | Invesco QQQ Equal Weight ETF | 29.16 | 4.41 | 17.83% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.